Related Companies
|
[]
|
||||||||
Related Funds
|
[]
|
||||||||
English
|
|||||||||
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
oda_UpdateAnnouncementFlag|
|
|
Evet (Yes)
|
|||||||
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
16.05.2022
|
|||||||
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_AnnouncementContentSection|
|
|
||||||||
oda_ExplanationSection|
|
|
||||||||
oda_ExplanationTextBlock|
|
-Unofficial Translation- Material Event Disclosure (https://www.kap.org.tr/tr/Bildirim/1030538 ) made about possible supply of the vaccine that developed by Moderna for Covid-19 ("SARS-CoV-2") with a Summary Info "Signing Local Representative and Services Agreement with Moderna Switzerland GMBH" With the subjected Agreement, an agreement was reached for GEN to be the sole supplier of the Moderna vaccine in Türkiye. Although the pandemic process of Covid-19 disease has slowed down, according to IQVIA estimates, it has been evluated that a total of 209 billion USD will be spent for Covid-19 vaccines and therapeutic drugs all over the world in the period between 2022 and 2026, and it is evaluated that the annual vaccine expenditures will be 30-40 billion USD in given period. It is considered that the disease will turn into endemic after the declaration of the end of the Covid-19 pandemic by the health authorities in our country, and the preventive methods to protect from the disease will continue to be used during the endemic period. The main purpose of the contract signed between GEN and Moderna is to develop solutions in our country for preventive measures to be used in the endemic period of the disease. It has been evluated that the this Agreement which was not take place on any projections previously made and disclosed (especially projections take place on Price Determination Report) by our company will start to be used in our country after legal process has been completed and it has been evaluated that it will have positive impact on our Company's total sales. |
We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.